Life long Maverick: Seen it ALLl in 40 yrs of PROF. exposure as invest analyst/port mgr on the FRONT lines vs iHub Msg Bds.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Unless someone has BETTER than Level 2 OTC screens, not likely you will get an answer: Screenshots posted to validate vs heresay!.
The DARK, DEEP, POWERFUL, ENTRENCHED & RELENTLESS FORCES which I have worked with many decades ago includes even High Profile Media (excluding AF) which for many years HERE & elsewhere have been SADLY for too MANY YEARS put on tertiary sideshow status since 2015! focusing solely on the clinical DC VAX L TRIAL which obviously no one here or elsewhere sensed it's extenuation!
From what time I have devoted to it, there has been IMHO a.....
DRAMATIC attenuation from PRE Federal Filing of Manipulating to AFTER .
BUT OTCN has been a noted leader POST Federal Filing to possibly offset that of cited:CDEL, CSTI, ETC.
THEY WILL Fight to the BITTER END IMHO because they have made TONS of $ on the BEAR Market
DIFFERENT STROKES for DIFFERENT FOLKS
I’d bet BSB would know their “handles.”
How about this:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141659228
Invariably, I DO get the LAST Laugh
DIFFERENT STROKES for DIFFERENT FOLKS
AF just put out another hit piece
(BIG DAH!)
DITTO done since 2014 for those comrades.....gangs that ply ALL message boards ... SEE DeepCapture.com especially the Dendreon section NONE of which since 2014 was ever acknowledged here PERIOD...
I directly witnessed firsthand how Wall Street really works especially in situations like this (Institutions BAILED NWBO at $7; I Bailed at $11+; Neil Woodford a 10% holder at $6.84 avg per share cost tried to fool everyone except moi!) since the 1980's as both:
1) an analyst at top tier Wall Street firms and dealt with high profile HEDGE FUNDS with a Short/Long orientation.
2) Discretionary Mooney Manager
AND
3)DESPITE the years here from 2014 till present FACED all the slings and arrows here! from most every imaginable viewpoint PERIOD: from even grandstanders here who got it wrong too many times to even posters on iHub Biotech Values message board.
When it's Oil AND Water:
Why BOTHER!
I even posted that despite a BEAR Market, the Stock Loan Departments of major Wall Street firms make a BIG Bundle of $ Lending Out retail accounts margined hypotheticated shares to SHORT HEDGE FUNDS
I am the least surprised of what has transpired since 2015 in this LONG EPIC SAGA!
UNLESS there emerges short term NWBO Strategic Partnerships and Deals of REAL substance to right the NWBO ship that will redress the IMBALANCE to date, expect more of the same!..........
by the Deep, Powerful DARK Nefarious forces that has been a growing force on Capital Markets PERIOD.
Barring the above.....
Down another road till one of 4 Regulatory Approvals for DCVAX L !
DIFFERENT STROKES for DIFFERENT FOLKS
JAMA Oncology
https://www.dr-bala.net/NWBO/jamaoncology_liau_2022.pdf
Would not be surprised with the ensuing
Partnership deals awaits.
1. Joint clinicals FUNDED by partner.
Many thousands of Checkpoint Inhibitor trials (CPI) have LOW response rates when there is a much higher response rate with NWBO’s technology platform
2) CASH Infusion
3) Significant NWBO EQUITY Interest above Mkt shr price to give NWBO Marquee status from much malignant innuendos that have been out to bury & bankrupt by so called “journalist”.
With the peer reviewed journal article
NWBO moves into a new life chapter.
Out of the Deep powerful DARK NEFARIOUS Wall St. forces and into the REAL world of complementing Big Pharma!
DIFFERENT STROKES for DIFFERENT FOLKS
"For a much needed timely reversal, for the GREATER GOOD, my sense (previously posted) that behind the thick curtains :
Partnership deal(S) with specific terms: IE:
1) Joint partnership clinical trials were? negotiated predicated upon Positive peer reviewed Journal publication.
(Big Pharma with their thousands of CheckPoint Inhibitor Clinical Trials do NEED the much higher response rates which NWBO's technology platform provides:
FUNDING, CASH Infusion and
likely significant equity interest in NWBO at well above Market Prices that
will give Marquee attention and CREDIBILITY VALIDATION to maligned NWBO when that party does with the consent of CEO Linda Powers & Bd of Directors does the ABOVE:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169867409
The above will avoid a threaded, since 2018: Reverse Stock Split, which I never harboured, posted accordingly..... in my reading between the lines of The Grand Strategist CEO Linda Powers who HAS pulled many LARGE Rabbits out of broken Hats since 2018! for all the solely scientific ones based here .
AND should the above transpire:
Presages for UPLISTING!
AND for other Biotech Investors I updated this today which I believe you may find interesting:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170495546
NASA: We are ready for LIFTOFF!
Since Fall of 2019:
Limited to ONE NWBO post daily: Can't reply.
The reason should be apparent to the cognesti to!
DIFFERENT STROKES for DIFFERENT FOLKS.
Immuno Oncology GAME CHANGER from the DARK Cellar (2017 at 15 cts) into
The LIGHT(now $1.14) ..........
for it's Moonshot?
PEER Reviewed & co-authored by more than 70 physicians from leading institutions across the U.S., Canada, U.K. and Germany:
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
followed by JAMA Audio Interview with DXVAX L's
Principal Investigator UCLA's Head of Oncology
Dr.Linda Liau PhD, MBA:
https://edhub.ama-assn.org/jn-learning/audio-player/18738384?resultClick=1
"Linda M. Liau is an American neurosurgeon, neuroscientist, and the W. Eugene Stern Chair of the Department of Neurosurgery at the David Geffen School of Medicine at UCLA. Liau was elected to the Society of Neurological Surgeons in 2013 and the National Academy of Medicine in 2018. Wikipedia
Books: Brain Tumor Immunotherapy
h-index: 77
Citations: 30,960
Affiliation: University of California, Los Angeles
Research interests: Brain Tumors, Brain Cancer, Neurosurgical Oncology"
DIFFERENT STROKES for DIFFERENT FOLKS
JAMA ONCOLOGY
November 17, 2022
Dear
We are very pleased to send you our most recent press release, announcing the featured publication in the peer reviewed cancer journal, JAMA Oncology, of the results of our Phase 3 trial of DCVax®-L for the treatment of Gliobastoma. The positive Topline Data from the trial include significant extensions of patient survival that have not been seen in many years of clinical trials for this aggressive brain cancer. Please use the link provided in the release to get the complete JAMA Oncology publication of our trial results.
Best,
Dave Innes
VP, Investor Relations
Northwest Bio?therapeutics, Inc.
4800 Montgomery Lane
Suite 800
Bethesda, MD 20814
t (240) 497-9024 ____www.nwbio.com
f (240) 627-4121 ____OTCQB: NWBO
For immediate release on November 17, 2022
Northwest Biotherapeutics Reports Positive Top-Line Results
From Phase 3 Trial of DCVax®-L for Glioblastoma
Both Median Survival and “Long Tail” of Extended Survival Were Increased
In Both Newly Diagnosed and Recurrent Glioblastoma
Results Featured In JAMA Oncology Peer Reviewed Publication
BETHESDA, Md., November 17, 2022 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today reported that in its Phase III clinical trial both median survival and the “long tail” of extended survival were increased in both newly diagnosed and recurrent glioblastoma brain cancer patients treated with DCVax®-L. The trial has met both the primary and the secondary endpoint under the Statistical Analysis Plan for the trial.
The trial results were reported today in a featured publication co-authored by more than 70 physicians from leading institutions across the U.S., Canada, U.K. and Germany, in the peer reviewed cancer journal JAMA Oncology, entitled “Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination with Extension of Survival Among Patients with Newly Diagnosed and Recurrent Glioblastoma”. https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
The Company believes this is the first time in nearly 20 years that a Phase III trial of a systemic treatment has shown such survival extension in newly diagnosed glioblastoma, and the first time in nearly 30 years that a Phase III trial of any type of treatment has shown such survival extension in recurrent glioblastoma.
Ms. Powers, CEO of NW Bio, commented: “We are excited to see the meaningful survival extensions in glioblastoma patients treated with DCVax®-L in this trial – particularly in the “long tail” of the survival curve, where we see more than double the survival rates as with existing standard of care. With well over 400 clinical trials for glioblastoma having failed over the last 15 years, it is gratifying to be able to offer new hope to patients who face this devastating disease.”
“It is especially encouraging to see these survival extensions with a treatment that has such a benign safety profile” Ms. Powers continued. “Over 2,100 doses of DCVax-L were administered during the trial, and we found that the adverse event profile was not meaningfully different than with standard of care alone. DCVax-L is also quite simple for the physician and patient: just an intradermal injection in the upper arm, 6 times over the course of year 1, and then twice a year for maintenance thereafter.”
Glioblastoma is the most common and most lethal form of primary brain cancer. Standard of care (SOC) treatments have been virtually unchanged for nearly 20 years. With SOC treatments, patients typically survive for only about 15-17 months from diagnosis, with the tumor recurring at about 6-8 months from diagnosis and the patients typically surviving for about 7-9 months after recurrence. Five-year survival from diagnosis is only about 5%.
In the Phase III trial of DCVax®-L, median Overall Survival (mOS) for newly diagnosed GBM patients (n=232) was 19.3 months from randomization (22.4 months from surgery) with DCVax-L vs. 16.5 months from randomization in the controls (HR=0.80, p=0.002). Survival at 48 months from randomization was 15.7% vs. 9.9%, and at 60 months was 13% vs. 5.7%. For recurrent GBM (n=64), mOS was 13.2 months from relapse vs. 7.8 months (HR = 0.58, p<0.001). Survival at 24 and 30 months post-recurrence was 20.7% vs. 9.6%, and 11.1% vs 5.1%, respectively. In newly diagnosed GBM patients with methylated MGMT, mOS was 30.2 months from randomization (33 months from surgery) with DCVax-L (n=90) vs. 21.3 months in controls (n=199) (HR=0.74, p=0.027).
From a safety perspective, out of more than 2,100 doses of DCVax-L administered during the Phase III trial, there were only 5 serious adverse events that were deemed at least possibly related to the treatment. There were 3 cases of intracranial edema, 1 case of nausea and 1 case of lymph node infection.
DCVax-L is a fully personalized immune therapy made from a patient’s own immune cells (dendritic cells) and antigens (biomarkers) from a sample of the patient’s own tumor. A multi-year set of doses is produced in a single manufacturing batch, which takes 8 days. The product is then stored frozen in individual doses, and is “off the shelf” throughout the treatment regimen. The doses are stored centrally and simply taken out of the freezer and delivered to the physician when needed for the patient’s next treatment.
Dr. Marnix Bosch, senior author on the publication, concluded “This DCVax-L trial, at 94 hospitals in 4 countries, involved the teamwork of a large number of dedicated investigators. Publication of the results in the prestigious, peer-reviewed journal JAMA Oncology honors this teamwork and demonstrates how the field can move forward with novel therapies and innovative clinical trial designs.”
The Company is currently working on preparations for applications for regulatory approval of DCVax®-L.
DIFFERENT STROKES for DIFFERENT FOLKS
Clearly the DARK NEFARIOUS Wall St forces by racheting up on the BID side & in SIZE without being filled as the ASK shows little size as the DARK forces are beginning to realize hopefully the INEVITABLE is coming shortly:
A TSUNAMI wave of trying to cover: especially
NAKED Shorts.
As long as believers and holders can restrain themselves from offering size on the ASK side and NOT hit the BID side ....
Will give the DARK POWERFUL NEFARIOUS forces some modicum of slight pain
They have made a GiNORMOUS BUNDLE in this BEAR MARKET.
Minor back & forth price actions are healthy
DIFFERENT STROKES for DIFFERENT FOLKS
Never thought from the beginning, there was any genuineness, let alone constructiveness or contribtion......
just bait for seduction.
For a much needed timely reversal, for the GREATER GOOD, my sense (previously posted) that this (Partnership deal with specific terms) will give Marquee attention when that party does with the consent of CEO Linda Powers & Bd of Directors does the following:
1) Takes a significant equity position (perhaps behind the curtain there has been a Silent Auction of sorts?) at well above what the marketplace thinks AND
2)Gives upfront significant cash sums to fund the beginning of an immuno -oncolgy clinical(S?)
3)Perhaps, as I posted many yearS ago, this may finally evolve like Genentech which some have only recently posted.
BOTH 1) & 2)to satisfy UPLISTING, and dispensing with yearS of marketplace apprehension re another reverse split which I addressed MANY years ago to finally put an end to this Long Term 3 Ring Circus!
BEFORE the above takes place:
First and FOREMOST: Publication of Peer Review on DC VAX L
The above is most logical long term evolution of this truly EPIC saga! ALL of which required the NWBO team overcoming MONUMENTAL obstacles to date on a myriad of fronts!
Our day should be upon us: certainly before Xmas when
A going to the Moon valuation takes place.
A long awaited NEW Life Chapter for NWBO BEGINS!
Have never had to revise my expressed views, which many still fail to own up to: lotS have LOST or have unrealized losses whereas I since 2015 have realized significant gains.
Only allowed ONE post per day for INFINITY
Life is what YOU make of it:
IRRESPECTIVE of the circumstances PERIOD.
DIFFERENT STROKES FOR DIFFERENT FOLKS.
Haven't seen since 2014, a BOLD call here that's been on the $. PERIOD But it will happen
Jacksonville, FL Mayo Clinic Dr. Keith Knutson FDA BC clinic work ran A BUZZER!
His work was for a former large holding TapImmune sold 2017 >$7 and ALL proceeds went into NWBO!
TapImmune has morphed into Marker Therapeutics now at 30's ish CENTS! and it's CEO I labelled in 2018 as a CARETAKER.. Former CEO was John Wilson. Their BC work USURPED!
EDIT
Purely RECALL:
A key SAB member (MexAmer) on NWBO who worked on DCVAX L trials left John Hopkins for Jacksonville Mayo Clinic to do run it's Neuro Oncology Operations!
From my extensive treasure troves:
"TapImmune Announces Commercialization Pathway For Its HER2neu Vaccine
Initiation of Company-Sponsored Phase 2 Clinical Trials will start early 2017
Jacksonville FL, November 1, 2016 – TapImmune, Inc. (OTCMKTS: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, is providing an update on the progression of a HER2neu vaccine into clinical trials. The vaccine (TPIV 110) consists of 4 proprietary Class II antigens and 1 proprietary Class I antigen. Both technologies were developed in the laboratory of Keith Knutson, Ph.D. and licensed from the Mayo Clinic.
In a Phase I clinical trial on the 4 Class II antigens in HER2neu breast cancer patients performed at the Mayo Clinic, over 90 percent of patients developed a robust T-cell response against these antigens. Data on the novel Class I antigen, published in J. Immunol. (2013), 190, 479-488, showed that it was a naturally processed antigen which was at least four times more effective at killing human breast cancer cells than previously tested class 1 antigens. There is growing scientific evidence to suggest the mixture of Class 1 and Class 2 antigens is essential for obtaining a robust immune response with potential therapeutic effects."
Why I rarely post!
MOVED ON.
DIFFERENT STROKES for DIFFERENT FOLKS
Still Adding despite the extenuating agony.
Found this interesting:
"NWBO BIGGEST OTCBB JULY TRADER"
4:08p ET 8/5/2022 - Benzinga
These 2 Under-The-Radar Stocks Traded More Than $1B Each Last Month
Mentioned: DANOY ETD ETHE GBTC IFNNY NGLOY NKE NLST NWBO RHHBY SIEGY UA UAA
For the OTCQB, these were the five stocks with the most volume in July:
CytoDyn Inc (OTC: CYDY): $37.1 million
Netlist, Inc. (OTC: NLST): $34.1 million
Freddie Mac (OTC: FMCC): $30.2 million
Fannie Mae (OTC: FNMA) $27.4 million
Northwest Biotherapeutics, Inc (OTC: NWBO): $22.7 billion
Been BORED here AND despite the expected INFLATION in the last year and OVER EXTENDED Market Valuations, I did unearth an unnamed cancer diagnostic test company that I was able to build a large position that frequently commucates and also covers the Long term opportunities posed by Long Covid & MonkeyPox which has attracted quite a rewarding following.
Life is what YOU make of it: IRRESPECTIVE of the circumstances.
Different Strokes for Different Folks.
GBM Agile Trial >1,000 patients
https://clinicaltrials.gov/ct2/show/NCT03970447
Kazia Therapeutics Shares Slide After Glioblastoma Study Update >KZIA
Mentioned: KZIA
By Colin Kellaher
U.S.-listed shares of Kazia Therapeutics Ltd. tumbled more than 40% on Monday after the Australian biotechnology company gave a disappointing update on the status of its lead program in a global study in glioblastoma, the most aggressive type of brain tumor.
Kazia said the first stage of the paxalisib arm of GBM Agile, a global adaptive clinical trial platform designed to evaluate multiple therapies for glioblastoma, completed recruitment but didn't meet pre-defined criteria for continuing to a second stage.
The company said patients enrolled in the first stage will continue on treatment and in follow-up until completion of the final analysis, expected in the second half of next year, but that study won't open to the paxalisib arm in Germany or China.
Kazia said it plans to work with its licensing partner to determine the path forward in China, given that country's general requirement for local data to register a new pharmaceutical product. The company licensed paxalisib from Roche Holding AG's Genentech unit in late 2016.
Kazia said it remains blinded to efficacy and safety data from the GBM Agile study, so it is unable to provide analysis or interpretation of the study until follow-up is complete and final data is available.
Kazia's U.S. shares were recently changing hands at $2.07, down 43%, after hitting a 52-week low of $1.63 earlier in the session.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 01, 2022 10:32 ET (14:32 GMT)
Life’s a beach for disgraced stockpicker Neil Woodford - The Times of London
June 13, 2022!
https://www.thetimes.co.uk/article/lifes-a-beach-for-disgraced-stockpicker-neil-woodford-xjchfwh76
DIFFERENT STROKES for DIFFERENT FOLKS
What Is the current status of Park West’s AVXL former 5% position re
Short Selling DOJ investigation
Apparent marketplace validation (13% on BIG volume:3.2 mln) of: still NO customer order despite the below:
Whatever the Wall St. promotions, let alone even MGT presentations, along with press releases LWLG are BACK to ReTest yet again former lows on BIG Volume.
Did any those BIG (multi Mens of shs of iINSIDERS seller’s in Dec 2021 at $17+ BUYBACK? IMHO adds a bad taste
Appears that LWLG is not the only disruptive player.
Glad at least I broke even in high $9’s.
Time tells all whether this becomes a REALITY or WHEN vs a Mirage?
Spooky.
DIFFERENT STROKES for DIFFERENT FOLKS
FDA screwed up! IMPLICATIONS for DC VAX L ?
[FDA withdraws approval for TG Therapeutics cancer treatment
Illustrative prime example of how the Pink Sheet market works which ties most ALL in knots is what has gone on with shorts on TNXP & THE REVERSAL which takes a lot of ENDURANCE that few could muster to produce what it did TODAY IMHO :
Also look at it's iHub board at posters.
IF one does some BASIC review it should be crystal clear and relevant to ALL non revenue Emerging Biotechs that has clearly mushroomed for the last THIRTY years.
Ignore at your peril.
Invariably, I do get the last laugh.
DIFFERENT STROKES for DIFFERENT FOLKS
Fortunately I sold and took a small loss!:
8:27a ET 5/31/2022 - Dow Jones
Outlook Therapeutics Withdraws Wet AMD Treatment Application
Mentioned: OTLK
By Will Feuer
Outlook Therapeutics Inc. said it has voluntarily withdrawn its biologics license application for its experimental wet age-related macular degeneration treatment while it responds to the U.S. Food and Drug Administration's request for additional information.
The company said it plans to re-submit a revised application for its experimental treatment, called ONS-5010, or bevacizumab-vikg, by September.
"We are continuing to have productive discussions with the FDA and are committed to providing the additional information necessary to support the application," Chief Executive Russell Trenary said. "We look forward to a successful resubmission and ultimately the potential approval of ONS-5010 for the treatment of wet AMD."
Shares of Outlook Therapeutics tumbled almost 38% to $1.05 in premarket trading.
ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration and other retinal diseases, Outlook Therapeutics said.
Some 1.8 million Americans aged 40 years and older are affected by age-related macular degeneration, according to the U.S. Centers for Disease Control and Prevention. Age-related macular degeneration is the leading cause of permanent impairment of reading and fine or close-up vision among people aged 65 years and older, the agency says.
DIFFERENT STROKES for DIFFERENT FOLKS
In the oven: Exotic James Beard Winning Whole Loaf vs burnt crumbs:
Congrats to the following DECIPHERiNG posters for the likely unfolding of major remaining waves of TSUNAMI @ASCO ETC w/shareholder unlikely to disapprove on pending SEC Form 14D proposal mainly requesting increase in authorized shares ETC:
FOREMOST BEFORE ASCO (ie STAT’s Matt Herper’s Interview: FDA Oncology Czar Pazdur) ….NWBO gets Peer Reviewed JOURNAL PUBLICATION & TDL PR for 2nd Wave of TSUNAMI (1st Wave was planned entrapment of SHORTS IMHO: ie Lawsuit & WHY No NYAS 5/10 Trading Halt) see:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168890433
Why Reefrad's phone call w/ David Innes responses is consistent with refreshingly Confirmatory Mi Dendream's post below AND why even on my only two calls( pre 2017!) ever to NWBO were to HELP them vs trying to get info:
AACR article published Wed May 11th!
by Executive Editor and founder of Cancer Connect.com Dr C.H.Weaver
ALSO: Why NO Trade Halt Tues May 10th:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168890433
AND NWBO Borrows Nose Dived from 1.4 Mln shs@105% last Fri @Noon to Tues close 65k@25%
The AACR Goods: was retrievable
https://news.cancerconnect.com/brain-cancer/dcvax-l-for-glioblastoma
SHINING BEACON Post for the AGES by BiosectInvestor
Everything Biosect spelled out I have experienced .
Biosect’s subtle hints over a week ago PRE NYAS Event + iwasadiver’s generous sharing POST NYAS event of his NYAS interaction with CEO Linda Powers and SVP Les Goldman HAVE revised my last posted view to one which I have harbored since late evening Wed May 11 TO:
SOLVING THE MYSTERY of Why CEO Linda Powers did what most all abhorred: NO TRADING HALT.
I compare it to: the 2018 HUMONGOUS campaign to Unseat CEO Linda Powers .
This is NO Different! IMHO:
The RANCOR since NYAS May 10th is deafening but hopefully not endemic.
THE ESSENCE & logic:
Due to the inability of NWBO to receive PRE NYAS event the long awaited expert peer reviewed JOURNAL Publication (final version was submitted late March, 2022 re iwasadiver) , CEO Linda Powers was put between a rock and a hard place PERIOD which typifies what some POTUS faces..
Tantamount are INFLUENCERS (Preeminent Neurosurgeons, RA’s, GBM’ers: ALL PRE ASCO and Shareholder’s in that SPECIFIC ORDER IF the current matrix faced by CEO Linda Powers allowed.
Sadly too few EVER, recall until it’s too late what I previously pointed out:
2019 ASM poignant remarks from BOTH SVP Les Goldman and CEO Linda Powers re SHORTS!
The above is THE ESSENCE of what has transpired vs ALL the NOISE since Monday May 9th….. exemplary of the last 7 years here PERIOD. Myopic focus at the expense of all else despite the clandestine Silence period there are BIG HINTS! which too few even entertain..
No one should be surprised IF after gestating on the above, that one may have a different view. That is why the world is in an ugly period.
As I’ve stated in numerous posts:
1)Emerging Biotechs are replete with IUDS: landmines galore.
2) Successful Investing is an Art Form.
3)Look into the MIRROR: SELF Inflicted issues: But instead play blame game!
Or worse unending war of words:image conscious
4)Lots of unending questions!: It’s only the RIGHT Answers that RESOLVE to allow one to move FORWARD
DIFFERENT STROKES for DIFFERENT FOLKS.
Thanks Biosectinvestor; iwasadiver; Doc_Logic AND lately The Danish Dude; CrashOverRide; Hoffman;
ALL of the DEVASTATION did not have to happen since Monday (pre NYAS event)IMHO and from those cited below IF:
As I and TcTrader and emphatically stated by BiosectInvestor have POSTED
1Q ‘22 SEC 10Q
BRIEF HILITES:
Ending 3/31/22 CASH $7 mln+ $8 mln (WRT Exercise) = $15 mln Cash (May 6, 2022)
AND
11. Subsequent Events
In total, the Company received $8.3 million from exercises of warrants and issuance of common stock between April 1, 2022 and May 6, 2022.
During April 2022, 7.7 million shares of common stock were issued upon warrant exercises for proceeds of approximately $2.0 million.
During April and May 2022, the Company received $6.3 million from issuance of 8.5 million shares of common stock to various investors. Approximately 1.7 million shares of common stock are pending to be issued.
Quickie: Does not appear to be any new disclosures.
DIFFERENT STROKES for DIFFERENT FOLKS
IMHO: CEO Linda Powers may request Trading HALT for OPTIMIZATION
Re TLD etc BEFORE ALL ELSE.
Then file SEC 14 Proxy
SURELY one should be aware that there ARE Quasi Institutions INVOLVED:
Neither the retail penny stock players, nor the market sponsorship by Small MicroCap or anyone here on iHub are ABLE to go toe to toe (second by second trading in at least the last 10 trading days (ie $15+ MILLION involved daily) to deal with the MM’s clearly doing their so called BIASED market stabilization mantra..
BTW after a five year absence on iHub’s BioTech Values posted this today:
Immuno Oncology GAME CHANGER:
Beatles: The Long & Winding Road leads tomorrow to:
May 10 at 11:10AM ET - "Autologous Tumor Lysate-loaded Dendritic Cell Vaccination for Glioblastoma"
https://events.nyas.org/event/28ca5e39-51a7-4e73-be3d-78089c92d596/websitePage:ccf12eed-4b47-487c-82af-faa589df6e0a
For discerning minds to unravel with your own DD.
Nevertheless:
THIS is still a PROCESS & The precursor of The Beginnings of a New Era for NWBO!
From more than TWICE near ASHES to The PHOENIX where The Legacies of Two Femme PHENOMS against Two Decades of INSURMOUNTABLES will be heralded for The Ages!
Do not have the time to respond.
Life is what YOU make of it: IRRESPECTIVE of the circumstances.
DIFFERENT STROKES for DIFFERENT FOLKS
SHOCKINGLY, 99% NEVER came across in their INcomplete Due Diligence What I POSTED in 2014 along with my years of exposure in 2002 to CEO Mitch Gold who ran a public healthcare SOFTWARE company I owned!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=104233666
Hoffman6383: A few years ago, under the same current strictures then, as is now, of only one NWBO post per day...
I prompted the "When Annual Meeting" with the below link and follow those replies AND do your own spadework for one's edification vs pollution:
Underscoring ongoing 3 ring circus with clowns on many repetitive fronts!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=153410209
WHEN one fits in the puzzling mosiac pieces of SEC 10K filing with that of SEC 14 Proxy Statement: https://www.sec.gov/answers/proxy.htm
along with Delaware Corp. requirements! to that of the timeline constraints of ASCO; delayed Journal publication;TLD
ONLY then does Darkness turn into DAWN....
The seemingly unending journey is nearing the beginning of a New Era from Caterpillar to Moth to BUTTERFLY!
DIFFERENT STROKES for DIFFERENT FOLKS
FWIW Fundamentally + TECHNICALLY:
Fundamentally: NO change from what I’ve been sporadically posting & clearly, unlike too many BOLD ONE’s, I have always taken it ONE step at a time ( lotS been cooking: awaiting percolation & initial confirmation that requires truly steely PATIENCE that has tested many for Ultimate unveiling.
Never easy to detach from one’s inherent NWBO BIASES!
However, my age old advice based on lots of front line experience is too divorce yourself from your NWBO experiences …. IF that’s possible and do this:
Pretend you know NOTHING about NWBO!…..
Based on what is in the public domain (ONLY SEC Filings & NWBO Press Releases) researching in depth, ALL as beautifully and COMPREHENSIVELY compiled for us by The Danish Dude :
https://knowwhatyouhold.com/t/banned-on-investorshub-ihub-to-be-continued-here/130
and the excellent current executive summary by Hoffman6383’s elaborate and discerning recent post vs “daily morsels by too many cooks inducing a migraine”
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168208945
Is NWBO a buy, or avoid?
Nevertheless:
THIS is still a PROCESS & The precursor of The Beginnings of a New Era for NWBO!with Journal publication followed by TLD
From more than TWICE near ASHES to The PHOENIX where
The Legacies of Two Femme PHENOMS against Two Decades of INSURMOUNTABLES will be heralded for The Ages!
HOWEVER:
TECHNICALLY
Based on my examining lotS of daily & weekly technical & sentiment indicatorS for NWBO stock, in contrast to that of many other Biotech’s, and the relevant comparable indexes…….it appears highly likely the potential of A POP from 71 CT’s in NWBO shs is before us…
Last week, despite the UKRAINE war news and geo politics AND economic fallout suggesting a worldwide SLOWDOWN , recession risks accelerating is before us, which I have intimated, I saw that both fundamentally & technically, along with sentiment indicators in my other biotech holdings were up dramatically by as much as 35% when the XBI not surprisingly under performed (3%) while ALL the major market averages +2% and market sectors were up!
Last week NWBO OUT PERFORMED (0.4%) while the XBI index ( 2.8%) highlighting what I witnessed in 75+ other selectively monitored emerging biotechs.
Since September 2019, I have been limited to one NWBO post daily for eternity and unlikely to reply.
Moreover, I have since 1970 covered the waterfront professionally and do have other challenging Insurmountables as priorities which I will overcome.
Life is what you make of it…. IRRESPECTIVE of the circumstances!
DIFFERENT STROKES for DIFFERENT FOLKS
NOT strangest NWBO trading I’ve seen: NEEDS to close above 85 cts!:
With the SLOW LOW NWBO volume yesterday (15 minutes before Wed close 250K! Hammered it DOWN: to produce a technical breakdown as seen here and indicated in Point & Figure commentary:
DOUBLE BOTTOM BREAKDOWN
https://stockcharts.com/freecharts/gallery.html?NWBO
Clear to me and VikingInvest ; SecureInvest; BiosectInvestor (THANKS to them!) & some others what is transpiring:
Apparently a band (TRIO+) of MANIPULATIVE Mkt Mkrs using their AI logo programs to INTIMIDATE and INDUCE selling to do some SHORT COVERING BEFORE Journal Publication/TLD given overall MKT DURESS with Russia/Ukraine, tomorrow’s Jobs Report AND today’s OIL $ spiking to $115 due to Saudi’s:
https://www.reuters.com/world/middle-east/saudi-crown-prince-plays-oil-card-quest-us-recognition-2022-03-03/
NOT helping are those with large CVM losses (>$200K: from $25 to $5) and NEED $ along with no more NWBO patience.
NWBO is my only biotech stock that is down today!
Will ADD.
Having a sense of the ENTIRE varied cast of characters:
1)NWBO Silence is Golden;
2)sharp SHORTS;
3)over extended penny stock players in a FROTHY overvalued CHANGED market place since FALL 2021 are the culprits IMHO.
“Know when to HOLD and when to fold.”
NWBO is NOT for the timid AND inexperience is magnified under the above conditions!
DIFFERENT STROKES for DIFFERENT FOLKS
Bright Boy Excellent Executive Summary (THANKS) & MOST need to delve into technical specifics on ASM, Proxy, RS & Uplisting: NONE are a walk in the park. It ALL relates to how one reads what’s CEO LP’s strategy AND the sequence & timing of ALL of the above as well as her likely undisclosed cards!
Bright Boy Excellent Executive Summary that encapsulates most all the salient points I've posted and harboured since my early involvement: fortunately I exited ALL at the top and only got back in many years later near the bottom of that precipitous roller coaster.
Now after the tortuous near death experiences since 2015 NWBO should be a Harvard Business School case study!
Today it took over 2 hours to fill my limit orders vs all other occasions!
The wild card is reading the historically intimidating antics of NITE.
BTW for CLARITY:
https://fintel.io/ss/us/
Nevertheless:
THIS is still a PROCESS & The precursor of The Beginnings of a New Era for NWBO!with Journal publication followed by TLD
From more than TWICE near ASHES to The PHOENIX where
The Legacies of Two Femme PHENOMS against Two Decades of INSURMOUNTABLES will be heralded for The Ages!
For the last 2+ years…Since I am only allowed one NWBO post per day along with my experience here since 2014, unlikely to expand on the time consuming complexities of the above
DIFFERENT STROKES FOR DIFFERENT FOLKS
Congrats Bala on new job
Unless you do an expensive move from northern LA Cty to Huntington Beach, it will take ~ 2 hrs one way door to door that will take a toll on you and your vehicle.
I did ~ the same door to door from
CT to midtown NYC daily for 20 yrs: BUT read daily the NYT + WSJ along with office work on the Metro north.
Luckily my younger son in law with your same credentials with a smart defense electronics backgound is working from home, Jackson, WY as a principal for Amazon.
Hopefully, with Journal publ, TLD RA approval your ideal will germinate so the above will be a short ordeal.
BTW: Everything I posted .. even the NASD Death Cross, along with Putin's goal of siding with Belarus...to Cyber attacking Estonia, Lithonia etc will have negative ongoing bear market consequences with higher interest rates and energy prices
DIFFERENT STROKES for DIFFERENT FOLKS
Better trade @Close: 66 K bought at 97 CT’s:
Apparently from same ETRD 66K@92 CT’s Bidder earlier in today’s session who did not take the 100K @93 CT’s CSTI Ask which was bought by a bigger buyer in one piece!
Well everything posted TRANSPIRED!:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167827981
1) CPI report today of highest inflation in FORTY years reminds me of Pres Carter: “ Let’s Lick INFLATION” pin.
then Fed Chairman Volcker raised interest rates BIG time to lick inflation: Home Mortgage rates went to 16%!
With ALL Short Term rates SPIKING to 2 yr highs ….the NASD Composite is nearing a Death Cross!
suggesting beyond a 10% market correction: Bear Market?
2) ALL market sectors broadly declined!…. Nothing goes straight down…
Remains to be seen whether despite the front running AVXL or LWLG can with their upcoming presentations get beyond “a Dead Cat Bounce” in this changed market environment.
NWBO has similar valuations but has much more to offer that should bowl over the market.
3) Despite the LONG wait and having to endure the “SILENCE is GOLDEN period since 2015!” NWBO looks finally primed and strategically positioned to BENEFIT in many ways with ALL the packaged goods behind the thick curtains ……once Journal Publication + TLD is delivered…… with much more behind it IMHO.
This time: “It’s Worth Staying in Tune” vs all the previous machinations or getting lost in the weeds! & hype here.
Far from the Maddening Crowd.
DIFFERENT STROKES for DIFFERENT FOLKS
Addressing KEY MARKERS!:
RE:
1) Checkpoint Inhibitors (CPI):
It has been established yearS ago that CPI have LOW Response Rates. Many hundreds of trials by the key players (who are potential NWBO buyers/partnership dealS would have an interest in NWBO's complementary platform AND it has much higher response rates vs CPI which I posted many yearS ago: look it up!)
2)Demystifying the contango re NWBO underperformance re XBI
KISS applies (Keep It Simple Stupid):
Previously addressed.. but way too many have never been a balanced portfolio manager undergoing The Fed BEHIND the Curve re Inflation AND since FALL 2021 of inflated Growth Stock Valuations which is why the riskiest market sector of Emerging biotechS or even the LARGE established Biotechs players such as INCY,SGEN,MRTX BIIB have been shellacked!
There are hundreds of Emerging biotechS like NWBO that have been WACKED much much worse! AND unlike NWBO have NOT rebounded since early Dec 2021.
With as many as 7 interest rate increases by respected interest rate market forecasters, market FUNDING will be more constraint and selective than what was witnessed in 2020-2021 with IPO rage.
Until one can OPEN that closed mindset of INexperience....one will be always waffling OR complaining re NWBO's strategy of "SILENCE is GOLDEN" which I advised LP in 2015.
3)Thank you SD_Investor_22 (our last interaction was late 2015!)for that example of acquiror's NOT shelving a product and for professionally validating and confirming my long held views re the Patents PROCESS: especially BEYOND Application and pursuing until GRANTED!
Nevertheless:
THIS is still a PROCESS & The precursor of The Beginnings of a New Era for NWBO!with Journal publication followed by TLD
From more than TWICE near ASHES to The PHOENIX where
The Legacies of Two Femme PHENOMS against Two Decades of INSURMOUNTABLES will be heralded for The Ages!
For the last 2+ years…Only allowed one NWBO post per day.
DIFFERENT STROKES FOR DIFFERENT FOLKS
The STRATEGIC CornerStone & Brilliance of CEO Linda Powers Deployment Game Plan seen here:
The LINKS below …..versus HERESAYs….demonstrates logically the real world fallacy of yearS of NWBO MOANERS (even bully pulpits) clamoring for earlier dissemination of TLD ….to understand……let alone, ………. break through, since at least 2015, the clandestine,steel nerved mindset of CEO Linda Powers!
https://ml.globenewswire.com/media/1b0f858f-4f7f-4f50-b691-a25307283fb5/small/anavexlogor-transparent-3x-png.png
SIX Minutes later:
STAT's Adam Feuerstein Tweets '...Anavex changed the primary and secondary endpoints of this Rett study on Jan. 18, alllowing it to claim success when the drug most likely failed. This press release is entirely misleading.'
Mentioned: AVXL
$AVXL - This is VERY important for people to see and understand.
— Adam Feuerstein ✡️ (@adamfeuerstein) February 1, 2022
Anavex changed the primary and secondary endpoints of this Rett study on Jan. 18, alllowing it to claim success when the drug most likely failed. This press release is entirely misleading. https://t.co/m6bpR0SeQY
Massive 125K offering near the close likely a PRELUDE to AH MSFT YrEND Qtrly CC:
MSFT AH (7.5+%!)
MSFT Forward Qtrly Guidance @ 5:30 PM Est!
Another Behemoth NVDA fell:
Bloomberg:” Nvidia Quietly Prepares to Abandon $40 Billion Arm Bid “
Anyone ever seriously thought about the already close to year long existing SHORTAGE of key semiconductors unable to supply some key customers with cars, gaming machines etc.
WHEREAS, LWLG needs to not only penetrate as a new customer with a sizable order to get the critical traction everyone believes is a shoo in!
Even Intel setting up massive Columbus,Ohio complex BEGINS operation in 2025!
So in the last ten days, I closed out my thoughts to you…my VALUATION PLUS reservations even though it had already declined from $19 to $11-$12 area.
Luckily due to both my investment and trading skills was able in 24 hours to BREAK EVEN and NOT take a seriously, rapid 25% HIT in a less than a week ……listening to NEOPHYTES not doing their own ongoing due diligence., but pandering to OTHERS is clearly evident.
Those institutions took their modest positions before Sept 2021 in a totally different market environment vs NOW!
Only 1 day up vs 13 DOzwN!
Rear view mirrors deployed by The Maddening Crowd.
DIFFERENT STROKES for DIFFERENT FOLKS.
NWBO in the past week & since Dec 2021 has exceeded ALL the indices by being UP versus:
U.S. Stocks Suffer Worst Week in 2 Years https://www.wsj.com/articles/nasdaq-s-p-finish-worst-week-since-march-2020-11642801144
Investors face reckoning as stock market has worst week since beginning of pandemic March 2020:
https://www.washingtonpost.com/business/2022/01/21/stock-market-selloff-2022/
As a former equity analyst and portfolio manager even dealing with top tier Hedge funds, I share my unwavering & bold views based on 40 years on The FRONT Lines.
Thanks to BOTH Jimmy667 and 10Bagg for their supportive responses in this recent thread:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167573593
For edification here is the back drop:
Literally sold a large position over 3 years ago in the following:
1)in predecessor MRKR at $7 over 3 years ago now 60 CT’s.
2)a large position in OMER in teens. , now $5+
Did all of the above to add to my NWBO position when it was below 20 CT’s.
Investing is an Art form….especially over MANY market cycles since 1999!
MORESO in Emerging Biotechs which tests one’s financial and mental fortitude in AVOIDING minefieldS GALORE! which have decapitated many!
Since FALL 2021 with my expectations of endemic Covid-19 continuing , rising inflation, and FED behind the Curve, I expected a shift from overvalued Growth situations to VALUE… all of which has transpired.
This is a CARDINAL Principle of successful Money Managers:ignore & suffer the perils!
THE MARKET is LARGER than anyone’s input.
At least NWBO in the past week even since it's last thrashing to 58 cents in early Dec 2021, NWBO has on ALL measures exceeded ALL the indices! where individual issues cited here
(NMTR, OTLK, LWLG, DTIL, KUHL:I fortunately avoided or sold EARLY for modest losses vs LARGE ones )
WHEN The MARKET undergoes such a dramatic Reversal from Growth to Value HUGMONGESS damage is inflicted AND with so much accelerating geopolitical and worldwide economic uncertainty it does not take much to unhinge the markets has been my assessment, especially given the HISTORICAL Bull Mkt Run due to Massive Worldwide Stimulus by US,EU, China, responding to the COVID-19 devastation that Bully Pulpits here & even former Administration both Dismissed & IGNORED!
Not surprisingly.... I do get the last laugh even though I have in last ~ 2 years been cordoned: indefinitely limited to one NWBO post per day.
Life is what YOU make of it,irrespective of the circumstances!
DIFFERENT STROKES for DIFFERENT FOLKS